argenx NV ADR (ARGX)vsGH Research PLC (GHRS)
ARGX
argenx NV ADR
$916.80
+5.82%
HEALTHCARE · Cap: $58.73B
GHRS
GH Research PLC
$26.17
-7.83%
HEALTHCARE · Cap: $1.95B
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 71/100 (B).
ARGX
Strong Buy71
out of 100
Grade: B
GHRS
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+61.9%
Fair Value
$2191.36
Current Price
$916.80
$1274.56 discount
Intrinsic value data unavailable for GHRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 193.8x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : GHRS
The strongest argument for GHRS centers on Debt/Equity, Altman Z-Score.
Bear Case : ARGX
The primary concerns for ARGX are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 41.7x leaves little room for execution misses.
Bear Case : GHRS
The primary concerns for GHRS are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while GHRS is a value play — different risk/reward profiles.
GHRS carries more volatility with a beta of 1.31 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (71/100 vs 23/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
GH Research PLC
HEALTHCARE · BIOTECHNOLOGY · USA
GH Research PLC is a clinical-stage biopharmaceutical company specializing in the development of psilocybin-based therapies targeted at psychiatric and neurodegenerative disorders. With a strong pipeline designed to meet significant unmet needs in mental health treatment, the company is led by an experienced team dedicated to advancing innovative therapeutic solutions. By leveraging its unique scientific approach, GH Research aims to transform treatment paradigms and improve patient outcomes, positioning itself as a potential leader in the burgeoning mental health therapeutics market.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?